• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Ionis-spinout Akcea prices IPO below expected range

July 14, 2017 By Sarah Faulkner

Akcea TherapeuticsCambridge, Mass.-based Akcea Therapeutics priced its offering of 15.6 million shares at $8 apiece to reach its $125 million IPO target. The company initially priced an offering of 9.6 million shares at $12 to $14 per share.

Akcea’s shares are slated to begin trading on the Nasdaq exchange today under the “AKCA.”

The biotech is a subsidiary of Ionis Pharmaceuticals (NSDQ:IONS) and is developing an injectable drug, volanesorsen, to treat rare lipid disorders that present with high levels of trigycerides and pancreatitis.

The company has conducted two late-stage trials of its drug as a therapy for patients with familial chylomicronemia syndrome. It is also running a Phase III trial for patients with familial partial lypodystrophy.

Akcea reported that the proceeds from its IPO will help commercialize volanesorsen and support more clinical trials.

In January, Novartis inked a collaborative deal with Akcea, forking over $75 million up front for the right to license and develop two drugs as potential therapies for cardiovascular disease.

Novartis also agreed to buy up $50 million in Akcea stock at the price set for its IPO.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Featured, Funding Roundup, Pharmaceuticals, Wall Street Beat Tagged With: akceatherapeutics, Ionis Pharmaceuticals

IN CASE YOU MISSED IT

  • Tandem Diabetes Care delivers 1 million insulin boluses using t:connect mobile app
  • Nuvo, Sheba Medical Center develop AI-powered gestational diabetes management platform
  • Verily’s Onduo, Sword Health collaborate on virtual diabetes care
  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Embecta stock soars on first full-quarter results after BD spinoff

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS